Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001654954-25-007737
Filing Date
2025-07-03
Accepted
2025-07-03 08:12:14
Documents
1
Period of Report
2025-07-01

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT section16.html 4  
1 PRIMARY DOCUMENT section16.xml 4 7702
  Complete submission text file 0001654954-25-007737.txt   9497
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Issuer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Business Address
Doogan Declan (Reporting) CIK: 0001704234 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34600 | Film No.: 251103799